CassandraBio
Pipeline dossier

NIH & clinical-trial pipeline signals for AbbVie Inc. (ABBV)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for ABBV, mapped to public ticker ABBV (CIK 0001551152). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →
Trial → FilingABBV35% conf

AbbVie Inc. (ABBV) — PHASE2 protocol updated 3 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)
trial ↗filings ↗
Trial → FilingABBV35% conf

AbbVie Inc. (ABBV) — PHASE2 protocol updated 6 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)
trial ↗filings ↗

Recent SEC 8-K filings

JSON API for this entity →